Skip to content
Poteligeo(mogamulizumab)
Poteligeo (mogamulizumab) is an antibody pharmaceutical. Mogamulizumab was first approved as Poteligeo on 2018-08-08. It is used to treat mycosis fungoides and sezary syndrome in the USA. It has been approved in Europe to treat mycosis fungoides and sezary syndrome. The pharmaceutical is active against C-C chemokine receptor type 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Poteligeo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mogamulizumab
Tradename
Proper name
Company
Number
Date
Products
Poteligeomogamulizumab-kpkcKyowa KirinN-761051 RX2018-08-08
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
poteligeoBiologic Licensing Application2020-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mycosis fungoides—D009182C84.0
sezary syndrome—D012751C84.1
Agency Specific
FDA
EMA
Expiration
Code
mogamulizumab, Poteligeo, Kyowa Kirin, Inc.
2025-08-08Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX09: Mogamulizumab
HCPCS
Code
Description
J9204
Injection, mogamulizumab-kpkc, 1 mg
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma cutaneousD016410C84.A131——5
Tropical spastic paraparesisD015493EFO_0007527G04.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8072———7
Adult t-cell leukemia-lymphomaD015459C91.533———6
Sezary syndromeD012751C84.134——16
Mycosis fungoidesD009182C84.043———5
T-cell lymphoma peripheralD016411C84.924———5
Large b-cell lymphoma diffuseD016403C83.311———1
Liver neoplasmsD008113EFO_1001513C22.011———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022891————1
Stomach neoplasmsD013274EFO_0003897C161————1
Esophageal neoplasmsD004938C151————1
Lung neoplasmsD008175C34.901————1
Kidney neoplasmsD007680EFO_0003865C641————1
Mouth neoplasmsD009062EFO_0003868C06.91————1
AsthmaD001249EFO_0000270J451————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMOGAMULIZUMAB
INNmogamulizumab
Description
Mogamulizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1159266-37-1
RxCUI2054068
ChEMBL IDCHEMBL1743041
ChEBI ID—
PubChem CID—
DrugBankDB12498
UNII IDYI437801BE (ChemIDplus, GSRS)
Target
Agency Approved
CCR4
CCR4
Organism
Homo sapiens
Gene name
CCR4
Gene synonyms
CMKBR4
NCBI Gene ID
1233
Protein name
C-C chemokine receptor type 4
Protein synonyms
C-C CKR-4, CCR-4, CD194, chemokine (C-C motif) receptor 4, chemokine (C-C) receptor 4, K5-5
Uniprot ID
Q9ULY7
Mouse ortholog
Ccr4 (12773)
C-C chemokine receptor type 4 (Q14A03)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,305 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
38,290 adverse events reported
View more details